Even Dividend Stocks Beating Palantir: Is It Time to Buy?
Palantir remains a topic of debate as dividend-focused peers outperform in choppy markets. Here’s how the latest move...
Want to earn the most rewards on your purchases? Check out our top credit card picks that provide outstanding reward programs.
28,031 articlesPalantir remains a topic of debate as dividend-focused peers outperform in choppy markets. Here’s how the latest move...
Crypto dollars are moving from the sidelines to the heart of American politics, with record 2024 spending and a growi...
A key on-chain signal points to a potential drop toward $700 for ethereum (eth), even as network activity grows and i...
Sarah Jessica Parker’s journey from a large, struggling family to a $200 million fortune highlights how grit and ambi...
Utah regulators move to revoke the license of Provo Canyon School, citing a pattern of health and safety failures. Th...
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
A biotech fund just boosted its Oruka Therapeutics position after a blistering rally. Here’s what the move signals ab...
Energy Select Sector SPDR Fund (XLE) has staged a rebound as crude hits higher levels. Two key signals could set the ...
Protests flare along the Albanian Adriatic coast over a Kushner-linked resort plan, pitting job hopes against environ...
FuelCell Energy jumps on a large data-center power deal, ahead of Plug Power and Bloom Energy, signaling potential su...
Ford faces renewed scrutiny as recalls mount and U.S. sales soften, fueling a debate over whether ford should give ba...
IonQ posted triple-digit revenue growth for 2025, reaching a new high, while losses intensified. The stock has fallen...